Clinical Trial Update: First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study of TSHA-101 gene therapy for infantile GM2 gangliosidosis is underway in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile Gm2 Gangliosidosis

Drugs mentioned

• TSHA-101

Snippet

Sponsor: Dr. Anupam Sehgal | Conditions: Infantile GM2 Gangliosidosis (Disorder) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING